medicalxpress.com
Why anti-TNF drugs don't work for some kids with Crohn's disease - Medical Xpress
This study suggests a common genetic marker (HLA‑DQA1*05) may help explain why some children stop responding to anti‑TNF drugs and could eventually guide who might benefit from adding methotrexate or closer monitoring.
Pediatric patients with Crohn's disease, parents and caregivers, pediatric gastroenterologists, and researchers studying genetics of treatment response.
What To Know
Researchers analyzed pediatric trial samples to examine whether the HLA‑DQA1*05 genetic allele is linked to anti‑TNF treatment failure and development of anti‑drug antibodies in children with Crohn's disease. The study used samples from a prior multi‑center randomized trial comparing anti‑TNF alone versus anti‑TNF plus methotrexate.
HLA‑DQA1*05 was common in the group and was associated with higher rates of antidrug antibodies and treatment failure, while combination therapy with methotrexate was linked to lower failure rates.
The article reports the findings without overstating them: some associations were not statistically significant, and the authors describe potential clinical uses (targeted genetic screening) as something they are not yet doing universally.
It notes common clinical responses when anti‑TNF drugs stop working—dose escalation, adding methotrexate, or switching therapies—and highlights the lack of pediatric‑approved alternatives.
If validated in larger studies, HLA‑DQA1*05 testing might help guide decisions about using combination therapy or monitoring for antibodies in children starting infliximab or adalimumab. For now, the research suggests a promising direction but does not change standard care.
Findings come from analysis of samples from a prior randomized trial; some associations reported were not statistically significant. This is early evidence toward using HLA testing to guide treatment; it does not yet mandate routine genetic screening or change treatment guidelines.
